{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:20:39Z","timestamp":1790709639724,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s40257-022-00686-z","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T18:04:06Z","timestamp":1650045846000},"page":"469-480","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Candida Infection Associated with Anti-IL-17 Medication: A Systematic Analysis and Review of the Literature"],"prefix":"10.1007","volume":"23","author":[{"given":"Mika","family":"Yamanaka-Takaichi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soha","family":"Ghanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Katzka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle R.","family":"Torgerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsaneh","family":"Alavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,15]]},"reference":[{"issue":"11","key":"686_CR1","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1177\/154405910508401101","volume":"84","author":"A Dongari-Bagtzoglou","year":"2005","unstructured":"Dongari-Bagtzoglou A, Fidel PL Jr. The host cytokine responses and protective immunity in oropharyngeal candidiasis. J Dent Res. 2005;84(11):966\u201377.","journal-title":"J Dent Res"},{"issue":"3","key":"686_CR2","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/art.39468","volume":"68","author":"E Salt","year":"2016","unstructured":"Salt E, Wiggins AT, Rayens MK, Huaman MA, Mannino D, Schwieterman P, et al. Risk factors for targeted fungal and mycobacterial infections in patients taking tumor necrosis factor inhibitors. Arthritis Rheum. 2016;68(3):597\u2013603.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"686_CR3","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40257-016-0206-4","volume":"17","author":"AW Armstrong","year":"2016","unstructured":"Armstrong AW, Bukhalo M, Blauvelt A. A clinician\u2019s guide to the diagnosis and treatment of candidiasis in patients with psoriasis. Am J Clin Dermatol. 2016;17(4):329\u201336.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"686_CR4","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.cgh.2018.04.035","volume":"17","author":"P Hoversten","year":"2019","unstructured":"Hoversten P, Otaki F, Katzka DA. Course of esophageal candidiasis and outcomes of patients at a single center. Clin Gastroenterol Hepatol. 2019;17(1):200-2.e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"686_CR5","doi-asserted-by":"crossref","unstructured":"Hoversten P, Kamboj AK, Katzka DA. Infections of the esophagus: an update on risk factors, diagnosis, and management. Dis Esophagus. 2018;31(12):doy094","DOI":"10.1093\/dote\/doy094"},{"issue":"922","key":"686_CR6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1136\/pmj.78.922.455","volume":"78","author":"A Akpan","year":"2002","unstructured":"Akpan A. Oral candidiasis. Postgrad Med J. 2002;78(922):455\u20139.","journal-title":"Postgrad Med J"},{"key":"686_CR7","doi-asserted-by":"publisher","first-page":"9602362","DOI":"10.1155\/2018\/9602362","volume":"2018","author":"A Pietrzak","year":"2018","unstructured":"Pietrzak A, Grywalska E, Socha M, Roli\u0144ski J, Franciszkiewicz-Pietrzak K, Rudnicka L, et al. Prevalence and possible role of Candida species in patients with psoriasis: a systematic review and meta-analysis. Mediat Inflamm. 2018;2018:9602362.","journal-title":"Mediat Inflamm"},{"key":"686_CR8","first-page":"1174748","volume":"2021","author":"M Chadeganipour","year":"2021","unstructured":"Chadeganipour M, Shadzi S, Mohammadi R. Fungal infections among psoriatic patients: etiologic agents, comorbidities, and vulnerable population. Autoimm Dis. 2021;2021:1174748.","journal-title":"Autoimm Dis."},{"issue":"6","key":"686_CR9","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.jaad.2012.11.033","volume":"68","author":"BL Picciani","year":"2013","unstructured":"Picciani BL, Michalski-Santos B, Carneiro S, Sampaio AL, Avelleira JC, Azulay DR, et al. Oral candidiasis in patients with psoriasis: correlation of oral examination and cytopathological evaluation with psoriasis disease severity and treatment. J Am Acad Dermatol. 2013;68(6):986\u201391.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"686_CR10","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/jcpt.13416","volume":"46","author":"C He","year":"2021","unstructured":"He C, Xue C, Zhu G, Kang P. Efficacy and safety of interleukin-17 inhibitors in the treatment of chronic rheumatic diseases: a combined and updated meta-analysis. J Clin Pharm Ther. 2021;46(4):895\u2013906.","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"686_CR11","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/BOR.0000000000000274","volume":"28","author":"CT Ritchlin","year":"2016","unstructured":"Ritchlin CT, Krueger JG. New therapies for psoriasis and psoriatic arthritis. Curr Opin Rheumatol. 2016;28(3):204\u201310.","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"686_CR12","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa2102383","volume":"385","author":"K Reich","year":"2021","unstructured":"Reich K, Warren RB, Lebwohl M, Gooderham M, Strober B, Langley RG, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385(2):142\u201352.","journal-title":"N Engl J Med"},{"issue":"2","key":"686_CR13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1084\/jem.20081463","volume":"206","author":"HR Conti","year":"2009","unstructured":"Conti HR, Shen F, Nayyar N, Stocum E, Sun JN, Lindemann MJ, et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med. 2009;206(2):299\u2013311.","journal-title":"J Exp Med"},{"issue":"1","key":"686_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/bjd.15015","volume":"177","author":"DM Saunte","year":"2017","unstructured":"Saunte DM, Mrowietz U, Puig L, Zachariae C. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol. 2017;177(1):47\u201362.","journal-title":"Br J Dermatol"},{"issue":"1","key":"686_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/0022034511399284","volume":"23","author":"PL Fidel Jr","year":"2011","unstructured":"Fidel PL Jr. Candida-host interactions in HIV disease: implications for oropharyngeal candidiasis. Adv Dent Res. 2011;23(1):45\u20139.","journal-title":"Adv Dent Res"},{"issue":"4","key":"686_CR16","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","volume":"371","author":"RG Langley","year":"2014","unstructured":"Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis: results of two phase 3 trials. N Engl J Med. 2014;371(4):326\u201338.","journal-title":"N Engl J Med"},{"issue":"1","key":"686_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2015.04.011","volume":"73","author":"U Mrowietz","year":"2015","unstructured":"Mrowietz U, Leonardi CL, Girolomoni G, Toth D, Morita A, Balki SA, et al. Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE). J Am Acad Dermatol. 2015;73(1):27-36.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"686_CR18","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/bjd.13814","volume":"173","author":"D Tha\u00e7i","year":"2015","unstructured":"Tha\u00e7i D, Humeniuk J, Frambach Y, Bissonnette R, Goodman JJ, Shevade S, et al. Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). Br J Dermatol. 2015;173(3):777\u201387.","journal-title":"Br J Dermatol"},{"issue":"2","key":"686_CR19","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/bjd.13348","volume":"172","author":"A Blauvelt","year":"2015","unstructured":"Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, et al. Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE). Br J Dermatol. 2015;172(2):484\u201393.","journal-title":"Br J Dermatol"},{"issue":"14","key":"686_CR20","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","volume":"373","author":"PJ Mease","year":"2015","unstructured":"Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329\u201339.","journal-title":"N Engl J Med"},{"issue":"9999","key":"686_CR21","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","volume":"386","author":"IB McInnes","year":"2015","unstructured":"McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137\u201346.","journal-title":"Lancet"},{"issue":"2","key":"686_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/bjd.14493","volume":"175","author":"KA Papp","year":"2016","unstructured":"Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273\u201386.","journal-title":"Br J Dermatol"},{"issue":"6","key":"686_CR23","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.jaad.2014.08.039","volume":"71","author":"K Papp","year":"2014","unstructured":"Papp K, Leonardi C, Menter A, Thompson EH, Milmont CE, Kricorian G, et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol. 2014;71(6):1183-90.e3.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"686_CR24","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1111\/bjd.14702","volume":"176","author":"K Yamasaki","year":"2017","unstructured":"Yamasaki K, Nakagawa H, Kubo Y, Ootaki K. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176(3):741\u201351.","journal-title":"Br J Dermatol"},{"issue":"14","key":"686_CR25","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","volume":"373","author":"M Lebwohl","year":"2015","unstructured":"Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318\u201328.","journal-title":"N Engl J Med"},{"issue":"6","key":"686_CR26","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/1346-8138.15343","volume":"47","author":"Y Yamaguchi","year":"2020","unstructured":"Yamaguchi Y, Takatsu N, Ootaki K, Nakagawa H. Long-term safety of brodalumab in Japanese patients with plaque psoriasis: an open-label extension study. J Dermatol. 2020;47(6):569\u201377.","journal-title":"J Dermatol"},{"issue":"1","key":"686_CR27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13075-020-2099-0","volume":"22","author":"B Combe","year":"2020","unstructured":"Combe B, Rahman P, Kameda H, Ca\u00f1ete JD, Gallo G, Agada N, et al. Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis. Arthritis Res Ther. 2020;22(1):14.","journal-title":"Arthritis Res Ther."},{"issue":"10163","key":"686_CR28","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Cheng-Chung Wei J, Dougados M, Mease P, Deodhar A, Maksymowych WP, et al. Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet. 2018;392(10163):2441\u201351.","journal-title":"Lancet"},{"issue":"2","key":"686_CR29","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/jdv.15242","volume":"33","author":"RG Langley","year":"2019","unstructured":"Langley RG, Kimball AB, Nak H, Xu W, Pangallo B, Osuntokun OO, et al. Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials. J Eur Acad Dermatol Venereol. 2019;33(2):333\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"686_CR30","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa2102388","volume":"385","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Bagel J, Papp KA, Yamauchi P, Armstrong A, et al. Bimekizumab versus adalimumab in plaque psoriasis. N Engl J Med. 2021;385(2):130\u201341.","journal-title":"N Engl J Med"},{"issue":"10273","key":"686_CR31","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Papp KA, Blauvelt A, Langley RG, Armstrong A, Warren RB, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397(10273):487\u201398.","journal-title":"Lancet"},{"issue":"5","key":"686_CR32","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.jaad.2020.05.105","volume":"83","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Papp KA, Merola JF, Gottlieb AB, Cross N, Madden C, et al. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study. J Am Acad Dermatol. 2020;83(5):1367\u201374.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"686_CR33","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1136\/annrheumdis-2020-216980","volume":"79","author":"D van der Heijde","year":"2020","unstructured":"van der Heijde D, Gensler LS, Deodhar A, Baraliakos X, Poddubnyy D, Kivitz A, et al. Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2020;79(5):595\u2013604.","journal-title":"Ann Rheum Dis"},{"issue":"10222","key":"686_CR34","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0140-6736(19)33161-7","volume":"395","author":"CT Ritchlin","year":"2020","unstructured":"Ritchlin CT, Kavanaugh A, Merola JF, Schett G, Scher JU, Warren RB, et al. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2020;395(10222):427\u201340.","journal-title":"Lancet"},{"issue":"2","key":"686_CR35","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jaad.2018.03.037","volume":"79","author":"KA Papp","year":"2018","unstructured":"Papp KA, Merola JF, Gottlieb AB, Griffiths CEM, Cross N, Peterson L, et al. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial. J Am Acad Dermatol. 2018;79(2):277-86.e10.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"686_CR36","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","volume":"77","author":"S Glatt","year":"2018","unstructured":"Glatt S, Baeten D, Baker T, Griffiths M, Ionescu L, Lawson ADG, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77(4):523\u201332.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"686_CR37","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028522","volume":"10","author":"L Monin","year":"2018","unstructured":"Monin L, Gaffen SL. Interleukin 17 family cytokines: signaling mechanisms, biological activities, and therapeutic implications. Cold Spring Harb Perspect Biol. 2018;10(4): a028522.","journal-title":"Cold Spring Harb Perspect Biol."},{"issue":"4","key":"686_CR38","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","volume":"62","author":"PG Pappas","year":"2016","unstructured":"Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-50.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"686_CR39","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.3390\/ijms22115794","volume":"22","author":"Y Sawada","year":"2021","unstructured":"Sawada Y, Setoyama A, Sakuragi Y, Saito-Sasaki N, Yoshioka H, Nakamura M. The role of IL-17-producing cells in cutaneous fungal infections. Int J Mol Sci. 2021;22(11):5794.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"686_CR40","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1099\/jmm.0.000095","volume":"64","author":"TG Campois","year":"2015","unstructured":"Campois TG, Zucoloto AZ, de Almeida Araujo EJ, Svidizinski TIE, Almeida RS, da Silva Quirino GF, et al. Immunological and histopathological characterization of cutaneous candidiasis. J Med Microbiol. 2015;64(8):810\u20137.","journal-title":"J Med Microbiol"},{"issue":"4","key":"686_CR41","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.tripleo.2009.11.026","volume":"109","author":"GR Thompson 3rd","year":"2010","unstructured":"Thompson GR 3rd, Patel PK, Kirkpatrick WR, Westbrook SD, Berg D, Erlandsen J, et al. Oropharyngeal candidiasis in the era of antiretroviral therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109(4):488\u201395.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"5","key":"686_CR42","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.oooo.2012.05.011","volume":"114","author":"AA Bedair","year":"2012","unstructured":"Bedair AA, Darwazeh AM, Al-Aboosi MM. Oral Candida colonization and candidiasis in patients with psoriasis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;114(5):610\u20135.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"issue":"4","key":"686_CR43","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/j.1439-0507.2011.02040.x","volume":"54","author":"M Ruhnke","year":"2011","unstructured":"Ruhnke M, Rickerts V, Cornely OA, Buchheidt D, Gl\u00f6ckner A, Heinz W, et al. Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses. 2011;54(4):279\u2013310.","journal-title":"Mycoses"},{"issue":"Suppl. 1","key":"686_CR44","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/S0001-7310(14)70016-X","volume":"105","author":"Y Ling","year":"2014","unstructured":"Ling Y, Puel A. IL-17 and infections. Actas Dermosifiliogr. 2014;105(Suppl. 1):34\u201340.","journal-title":"Actas Dermosifiliogr"},{"key":"686_CR45","doi-asserted-by":"crossref","unstructured":"Verma AH, Richardson JP, Zhou C, Coleman BM, Moyes DL, Ho J, et al. Oral epithelial cells orchestrate innate type 17 responses to Candida albicans through the virulence factor candidalysin. Sci Immunol. 2017;2(17):eaam8834.","DOI":"10.1126\/sciimmunol.aam8834"},{"key":"686_CR46","doi-asserted-by":"crossref","unstructured":"Aggor FEY, Break TJ, Trevejo-Nu\u00f1ez G, Whibley N, Coleman BM, Bailey RD, et al. Oral epithelial IL-22\/STAT3 signaling licenses IL-17-mediated immunity to oral mucosal candidiasis. Sci Immunol. 2020;5(48):eaba0570.","DOI":"10.1126\/sciimmunol.aba0570"},{"issue":"11","key":"686_CR47","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","volume":"157","author":"S Glatt","year":"2021","unstructured":"Glatt S, Jemec GBE, Forman S, Sayed C, Schmieder G, Weisman J, et al. Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial. JAMA Dermatol. 2021;157(11):1279\u201388.","journal-title":"JAMA Dermatol"},{"key":"686_CR48","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.3389\/fimmu.2020.01894","volume":"11","author":"R Adams","year":"2020","unstructured":"Adams R, Maroof A, Baker T, Lawson ADG, Oliver R, Paveley R, et al. Bimekizumab, a novel humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Front Immunol. 2020;11:1894.","journal-title":"Front Immunol"},{"key":"686_CR49","doi-asserted-by":"crossref","unstructured":"Messer SA, Moet GJ, Kirby JT, Jones RN. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007). J Clin Microbiol. 2009;47(6):1942\u20136.","DOI":"10.1128\/JCM.02434-08"},{"issue":"6","key":"686_CR50","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1046\/j.1365-4362.1998.00496.x","volume":"37","author":"B Amichai","year":"1998","unstructured":"Amichai B, Grunwald MH. Adverse drug reactions of the new oral antifungal agents: terbinafine, fluconazole, and itraconazole. Int J Dermatol. 1998;37(6):410\u20135.","journal-title":"Int J Dermatol"},{"issue":"1","key":"686_CR51","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/j.1471-0528.2002.01142.x","volume":"109","author":"MC Watson","year":"2002","unstructured":"Watson MC, Grimshaw JM, Bond CM, Mollison J, Ludbrook A. Oral versus intra-vaginal imidazole and triazole anti-fungal agents for the treatment of uncomplicated vulvovaginal candidiasis (thrush): a systematic review. BJOG. 2002;109(1):85\u201395.","journal-title":"BJOG"},{"issue":"2","key":"686_CR52","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0002-9378(98)80001-X","volume":"178","author":"JD Sobel","year":"1998","unstructured":"Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR, et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol. 1998;178(2):203\u201311.","journal-title":"Am J Obstet Gynecol"},{"key":"686_CR53","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.3389\/fimmu.2019.03096","volume":"10","author":"E von Stebut","year":"2019","unstructured":"von Stebut E, Boehncke WH, Ghoreschi K, Gori T, Kaya Z, Thaci D, et al. IL-17A in psoriasis and beyond: cardiovascular and metabolic implications. Front Immunol. 2019;10:3096.","journal-title":"Front Immunol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00686-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-022-00686-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00686-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T16:52:30Z","timestamp":1659113550000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-022-00686-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,15]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["686"],"URL":"https:\/\/doi.org\/10.1007\/s40257-022-00686-z","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,15]]},"assertion":[{"value":"15 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No sources of funding were received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Mika Yamanaka-Takaichi, Soha Ghanian, David A, Katzka, and Rochelle R. Torgerson have no conflicts of interest to disclose. Afsaneh Alavi is a consultant for AbbVie, BI, Janssen, InflaRx, Novartis, and UCB and an investigator for BI, Processa, and Castle Creek.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"MYT and SG performed the literature review and DAK, RRT, and AA edited the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}